Overview

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The study was designed to obtain data about the efficacy and safety of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese patients with chronic obstructive pulmonary disease (COPD) so that optimal dose(s) could be chosen for testing in later studies.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis